0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement: A Randomized, Double-Blind, Placebo-Controlled Trial

John A. Heit, MD; C. Gregory Elliott, MD; Arthur A. Trowbridge, MD; Bernard F. Morrey, MD; Michael Gent, DSc; Jack Hirsh, MD, Ardeparin Arthroplasty Study Group*
[+] Article and Author Information

From the Mayo Clinic and Foundation, Rochester, Minnesota; LDS Hospital and the University of Utah School of Medicine, Salt Lake City, Utah; Texas A&M University College of Medicine, Temple, Texas; and McMaster University, Hamilton, Ontario, Canada.


Acknowledgments: The authors thank the surgical, nursing, pharmacy, and support staff at all the study sites. They also thank Dr. D. Scott Holloway and Ms. Joanne DiLiberto, Wyeth-Ayerst Research.

Grant Support: By Wyeth-Ayerst Research, Philadelphia, Pennsylvania.

Requests for Single Reprints: John A. Heit, MD, Hematology Research, Plummer 549, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints@mail.acponline.org.

Current Author Addresses: Dr. Heit: Hematology Research, Plummer 549, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.

Dr. Elliott: LDS Hospital, University of Utah, Eighth Avenue and C Street, Salt Lake City, UT 84143.

Dr. Trowbridge: Texas A&M University, 2401 South 31st Street, Temple, TX 76508.

Dr. Morrey: Mayo Clinic, 200 First Street, SW, Rochester, MN 55905.

Drs. Gent and Hirsh: Hamilton Civic Hospitals Research Centre, 711 Concession Street, Hamilton, Ontario L8V 1C3, Canada.

Author Contributions: Conception and design: C.G. Elliott, B.F. Morrey, J.A. Heit, J. Hirsh.

Analysis and interpretation of the data: C.G. Elliott, A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.

Drafting of the article: A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.

Critical revision of the article for important intellectual content: C.G. Elliott, A.A. Trowbridge, M. Gent, J.A. Heit, J. Hirsh.

Final approval of the article: C.G. Elliott, A.A. Trowbridge, B.F. Morrey, J.A. Heit, J. Hirsh.

Provision of study materials or patients: C.G. Elliott, A.A. Trowbridge, J.A. Heit, B.F. Morrey.

Statistical expertise: M. Gent.

Administrative, technical, or logistic support: M. Gent.

Collection and assembly of data: C.G. Elliott, J.A. Heit.


Ann Intern Med. 2000;132(11):853-861. doi:10.7326/0003-4819-132-11-200006060-00002
Text Size: A A A

The optimal duration of prophylaxis against venous thromboembolism after elective total hip or knee replacement is uncertain. In previous clinical trials, prophylaxis was given until hospital discharge and ranged from 7 to 14 days. However, the prevalence of asymptomatic deep venous thrombosis at hospital discharge was still approximately 15% for patients who had total hip replacement and 30% for those who had total knee replacement (1). Because most patients are now discharged by the third or fourth postoperative day, in-hospital prophylaxis may be inadequate.

First Page Preview

View Large
First page PDF preview

Figures

Grahic Jump Location
Figure 1.
Flow diagram of study design, drug intervention, patient enrollment, patient withdrawal, discontinuation of prophylaxis with the study drug, and duration of follow-up.

THR = total hip replacement; TKR = total knee replacement; SC = subcutaneously.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Duration of part A ardeparin sodium prophylaxis according to out-of-hospital prophylaxis assignment, overall and among patients who had efficacy failure.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Use of a New Form of the Blood Thinner Heparin Outside the Hospital To Prevent Blood Clots after Hip or Knee Replacement

The summary below is from the full report titled “ Ardeparin Sodium for Extended Out-of-Hospital Prophylaxis against Venous Thromboembolism after Total Hip or Knee Replacement. A Randomized, Double-Blind, Placebo-Controlled Trial.” It is in the 6 June 2000 issue of Annals of Internal Medicine (volume 132, pages 853-861). The authors are J.A. Heit, C.G. Elliott, A.A. Trowbridge, B.F. Morrey, M. Gent, and J. Hirsh, for the Ardeparin Arthroplasty Study Group.

Read More...

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)